Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

PTC Therapeutics Q1 2024 GAAP EPS $(1.20) Beats $(1.29) Estimate, Sales $210.118M Beat $169.703M Estimate

Author: Benzinga Newsdesk | April 25, 2024 04:39pm
PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(1.20) per share which beat the analyst consensus estimate of $(1.29) by 6.98 percent. The company reported quarterly sales of $210.118 million which beat the analyst consensus estimate of $169.703 million by 23.82 percent. This is a 4.66 percent decrease over sales of $220.382 million the same period last year.

Posted In: PTCT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist